Stockwatch: Pantomime Season Comes Early
This article was originally published in Scrip
The critiques and revelations surrounding the business practices of Valeant Pharmaceuticals International Inc. continued last week with a second successive Monday morning press conference to refute some of the more recent accusations levelled against it. This was followed by a Friday morning marathon press conference held by one of its biggest hedge fund shareholders in an attempt to recover some of the value lost from the fund's Valeant holding. The revelations and refutations concerning Valeant have come to resemble a pantomime with the company in the role of villain, and the list of traditional pantomime characters was bolstered by companies reporting their third-quarter earnings last week.
You may also be interested in...
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.
Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down
What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.